Hyperuicemia and cancer
10.3760/cma.j.issn.1000-6699.2016.05.018
- VernacularTitle:高尿酸血症与癌症
- Author:
Mian WU
;
Haibing CHEN
- Publication Type:Journal Article
- Keywords:
Hyperuricemia;
Cancer;
Xanthine oxidoreductase
- From:
Chinese Journal of Endocrinology and Metabolism
2016;32(5):429-432
- CountryChina
- Language:Chinese
-
Abstract:
[Summary] Hyperuricemia is a syndrome caused by increased production or reduced excretion of uric acid which is characterized by oliguria, anuria, and uremia. Recent studies found that hyperuricemia was correlated with the risk, recurrence, metastasis, and prognosis of cancer. The mechanism may be uric acid associated chronic inflammation and decrease of xanthine oxidoreductase expression in cancer cells. Current treatment of hyperuricemia is to reduce the production of uric acid by inhibition of xanthine oxidoreductase, but the side effects of systemic inhibition of xanthine oxidoreductase received more and more attention. These unwanted side effects underscore the urgent need for mechanism based preclinical studies that can identify optimal strategies for management of hyperuricemia in relevant cancer models.
